By flipping a Notch-signaling switch, researchers grew functional helper T cells from stem cells at scale — a step toward ready-made cell therapies that skip per-patient manufacturing.
Refreshed shots from Pfizer, Moderna and Novavax are updated for the now-dominant XFG strain — but this season’s approvals come with narrower eligibility than in past years.
Spanish researchers built molecules that switch on in light and stand in for lost photoreceptors, reawakening the retina’s surviving circuitry in animals blinded by degeneration.
Rusfertide mimics the body’s iron-regulating hormone to rein in red-blood-cell overproduction — and in a trial, most patients no longer needed regular blood draws.
The FDA expanded tirzepatide’s label to include cutting cardiovascular risk in type 2 diabetes — a first for a GIP/GLP-1 drug and a boost for the world’s top-selling medicine.
Michael Polansky’s Outer Bio launched with $23M and an unusual pitch: not a drug company, but an AI platform screening compounds on living human skin.
Sequencing eight Myotis bat species uncovered genetic tricks linking their famous virus tolerance to cancer resistance and longevity — clues that could inform human aging research.
Using Britain’s postwar sugar rationing as a natural experiment, researchers found that lower early-life sugar exposure tracked with less cancer and slower biological aging decades on — though it can’t prove cause.
The TSLP-blocking antibody met its goals in a Phase 3 eosinophilic esophagitis trial, setting up a potential third indication and a challenge to Sanofi’s Dupixent.
Priovant’s brepocitinib is the first pill approved for the rare autoimmune disease — in a trial, more patients improved and got off steroids than on placebo.
By deliberately removing the antibody response that can backfire against dengue, researchers built an experimental Zika vaccine that defended mice using T cells instead.
Nipocalimab wins FDA approval for warm autoimmune hemolytic anemia — a disease in which the immune system destroys the body’s own red blood cells — giving patients their first dedicated therapy.